We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
Projects granted during 2015 that have a primary purpose of multisystemic research.
Projects granted during 2015 with a primary purpose of basic research: nervous system.
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
Regular UKHSA updates on the ongoing investigation into higher than usual rates of liver inflammation (hepatitis) in children across the UK.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
You should take caution when you use NSAIDs in patients with renal impairment or are at risk.
(All manufacturers) inflammatory or granulomatous mass formation at the catheter tip causes a risk of temporary or permanent neurological impairment. (MDA/2008/038)
Thousands more NHS patients who are hospitalised due to COVID-19 will be able to receive the life-saving treatment tocilizumab, the government has announced.
Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases.
A new clinical trial will investigate whether a third dose of vaccine for people with weakened immune systems gives a stronger immune response than 2 doses.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.